Zobrazeno 1 - 10
of 596
pro vyhledávání: ''
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 6, Iss 1, Pp 1-7 (2021)
Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy
This study (ORIENT-4) aimed to assess the efficacy and safety of sintilimab, a humanized anti-PD-1 antibody, in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL). ORIENT-4 is a multicenter, single-arm, phase 2 clinical trial
Autor:
Jun Liu, Dan-Dan Li, Wei Dong, Yu-Qi Liu, Yang Wu, Da-Xuan Tang, Fu-Chun Zhang, Meng Qiu, Qi Hua, Jing-Yu He, Jun Li, Bai Du, Ting-Hai Du, Lin-Lin Niu, Xue-Jun Jiang, Bo Cui, Jiang-Bin Chen, Yang-Gan Wang, Hai-Rong Wang, Qin Yu, Jing He, Yi-Lin Mao, Xiao-Fang Bin, Yue Deng, Yu-Dan Tian, Qing-Hua Han, Da-Jin Liu, Li-Qin Duan, Ming-Jun Zhao, Cui-Ying Zhang, Hai-Ying Dai, Ze-Hua Li, Ying Xiao, You-Zhi Hu, Xiao-Yu Huang, Kun Xing, Xin Jiang, Chao-Feng Liu, Jing An, Feng-Chun Li, Tao Tao, Jin-Fa Jiang, Ying Yang, Yao-Rong Dong, Lei Zhang, Guang Fu, Ying Li, Shu-Wei Huang, Li-Ping Dou, Lan-Jun Sun, Ying-Qiang Zhao, Jie Li, Yun Xia, Fan Liu, Wen-Jin He, Jian-Cong Tan, Yang Lin, Ya-Bin Zhou, Jian-Fei Yang, Guo-Qing Ma, Hui-Jun Chen, He-Ping Liu, Zong-Wu Liu, Jian-Xiong Liu, Xiao-Jia Luo, Xiao-Hong Bin, Ya-Nan Yu, Hai-Xia Dang, Bing Li, Fei Teng, Wang-Min Qiao, Xiao-Long Zhu, Bing-Wei Chen, Qi-Guang Chen, Chun-Ti Shen, Yong-Yan Wang, Yun-Dai Chen, Zhong Wang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 6, Iss 1, Pp 1-10 (2021)
Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy
It’s a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in the differentiated populations with complex diseases, as stable coronary heart disease. Here, in an adaptive, 31-cente
Autor:
Ling Li, Quanxin Long, Li Liu, Xiaoyong Zhang, Yanqun Wang, Hong Zhu, Sheng Nie, Ailong Huang, Jinlin Hou, Xin Xu, Jian Sun, Fan Fan Hou, Jincun Zhao, Qinglang Zeng
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 6, Iss 1, Pp 1-7 (2021)
Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy
Our understanding of the protective immunity, particularly the long-term dynamics of neutralizing antibody (NAbs) response to SARS-CoV-2, is currently limited. We enrolled a cohort of 545 COVID-19 patients from Hubei, China, who were followed up up t
Autor:
Yan Gao, Jun Cai, Yi Xia, Qingqing Cai, Shuyun Ma, Yuchen Zhang, Lirong Li, Xiaopeng Tian, Hang Yang, Panpan Liu, Yajun Li, Xuanye Zhang, Hui Zhou, Huiqiang Huang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 5, Iss 1, Pp 1-9 (2020)
Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy
Advanced natural killer/T cell lymphoma (NKTL) has demonstrated poor prognosis with currently available therapies. Here, we report the efficacy of anti-programmed death 1 (PD-1) antibody with the P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) r
Autor:
Audrey Bidet, Hubert Serve, Pierre-Yves Dumas, Carsten Müller-Tidow, Josefina Serrano, Teresa Bernal, Sarah Bertoli, Juan Bergua, Eduardo Rodriguez Arbolí, Uwe Platzbecker, Pilar Martínez-Sánchez, Martin Bornhäuser, Eric Delabesse, Adolfo de la Fuente Burguera, Christian Recher, Arnaud Pigneux, Michael Kramer, Claudia D. Baldus, David Martínez-Cuadrón, Pau Montesinos, Emilie Bérard, Cristina Gil, Christoph Röllig, Suzanne Tavitian
Publikováno v:
Leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
LEUKEMIA
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
LEUKEMIA
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric Europ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c4fd2308cc3bead0a723ebfdc6b70e7
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15187
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15187
Autor:
Yabo Ouyang, Dexi Chen, Lijun Pang, Xianghua Guo, Ronghua Jin, Jiming Yin, Ying-Mei Feng, Hongbo Shi, Honglin Shi, Wenjing Wang, Luxin Qiao
Publikováno v:
Cell Death and Disease, Vol 11, Iss 6, Pp 1-8 (2020)
Cell Death & Disease
Cell Death & Disease
Background: Although most patients with COVID-19 pneumonia have a good prognosis, some patients develop to severe or critical cases, and the mortality of critical cases was up to 61.5%. However, specific information and molecular mechanism about crit
Autor:
Camilla Krakstad, Gordon B. Mills, Ingfrid S. Haldorsen, Madeleine Myrvold, Jone Trovik, Zhenlin Ju, Hege Fredriksen Berg, Kristine Eldevik Fasmer, Mari K. Halle, Erling A. Hoivik, Henrica M.J. Werner, Shannon N. Westin
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 122(7), 1014-1022. Nature Publishing Group
British Journal of Cancer, 122(7), 1014-1022. Nature Publishing Group
BackgroundIn endometrioid endometrial cancer (EEC), current clinical algorithms do not accurately predict patients with lymph node metastasis (LNM), leading to both under- and over-treatment. We aimed to develop models that integrate protein data wit
Publikováno v:
Cancer Gene Therapy, 27(1-2), 30-37. Nature Publishing Group
Acute myeloid leukemia (AML) is a clonal and heterogeneous disease characterized by a myriad of genetic defects. Genetic abnormalities are powerful prognostic factors. P21-activated kinases (PAKs) are a kind of serine/threonine protein kinases, which
Autor:
Sabine Siesling, Linda de Munck, Gerard J. den Heeten, Geertruida H. de Bock, Jacques Fracheboud, Mireille J. M. Broeders
Publikováno v:
British Journal of Cancer, 123(7), 1191-1197. Nature Publishing Group
British Journal of Cancer
British journal of cancer, 123(7), 1191-1197. Nature Publishing Group
British Journal of Cancer
British journal of cancer, 123(7), 1191-1197. Nature Publishing Group
Background To estimate the percentages of advanced-stage breast cancers (BCs) detected during the course of a steady-state screening programme when using different definitions of advanced BC. Methods Data of women aged 49–74 years, diagnosed with B
Autor:
Maximilian Merz, Anna Jauch, Peter Brossart, Jan Duerig, Hartmut Goldschmidt, Dirk Hose, Steffen Luntz, Britta Besemer, Elias K. Mai, Ahmet H. Elmaagacli, Anja Seckinger, Markus Munder, Stephan Fuhrmann, Hans-Walter Lindemann, Uta Bertsch, Marc S. Raab, Igor Wolfgang Blau, Christian Jehn, Hans Salwender, Katja Weisel, Axel Benner, Kaya Miah, Mathias Haenel, Christof Scheid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c3e93f399758e8aa52c01b85b8ed62d
https://hdl.handle.net/20.500.14017/a78230dc-1b15-42b4-b98b-770e800164f1
https://hdl.handle.net/20.500.14017/a78230dc-1b15-42b4-b98b-770e800164f1